eritoran synthetic lipid inhibits receptor developed potential treatment severe sepsis excessive inflammatory response infection failed five year phase iii clinical trial results published longer developed japanese pharmaceutical company eisai co administered intravenously sodium salt eritoran part innate immune system plays important role triggering defense pathogens eritoran similar structure lipopolysaccharide lipid part bacteria binds activates triggering defense eritoran binds blocks much signalling may part causes cytokine storms sepsis drug inhibits shown prevent treat sepsis cytokine storms httpsenwikipediaorgwikieritoran